MBRX Files 8-K Attaching Q2 2025 Earnings Press Release

Rhea-AI Filing Summary

Moleculin Biotech, Inc. disclosed that it issued a press release reporting its financial results for the quarter ended June 30, 2025 and recent operational highlights. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into the filing.

The 8-K filing itself does not present numerical revenue, profit, cash flow or balance sheet figures; investors must consult the attached press release for detailed results and metrics. The company’s common stock trades under the ticker MBRX on The NASDAQ Stock Market. The filing also lists an Inline XBRL cover page as Exhibit 104, indicating machine-readable cover data is included with the submission.

Positive

• Press release included as Exhibit 99.1, formally incorporating the company announcement into the SEC record
• Inline XBRL cover page is provided, supporting machine-readable filing data

Negative

• No numerical financial figures are presented in the 8-K text; the filing points readers to Exhibit 99.1 for results
• No operational detail or line-item metrics are included within the 8-K itself

Insights

Financial Analyst

TL;DR: Form 8-K attaches a press release with Q2 2025 results; the 8-K text contains no numerical financial data.

The filing formally incorporates a press release announcing financial results for the quarter ended June 30, 2025 and operational highlights by reference to Exhibit 99.1. No revenue, net income, EPS, cash position or other line-item financials are presented within the 8-K itself, so material financial detail must be obtained from the press release. Inclusion of Exhibit 104

Securities Compliance Analyst

TL;DR: Routine disclosure filing to make an earnings press release part of the SEC record; not itself a standalone earnings statement.

The document is a procedural Form 8-K that attaches and incorporates a press release reporting quarter-end results and recent operational highlights. The filing lists two exhibits: 99.1 104

false 0001659617 0001659617 2025-08-13 2025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 13, 2025

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b- 2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01         Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated August 13, 2025
104	Cover page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.
	Date: August 13, 2025
	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster
		Chief Financial Officer

FAQ

What did Moleculin Biotech (MBRX) disclose in this 8-K?

The company announced a press release reporting financial results for the quarter ended June 30, 2025 and recent operational highlights, and attached that press release as Exhibit 99.1.

Does the Form 8-K include the company’s financial statements or numeric results?

No. The 8-K text does not present revenue, earnings or balance sheet figures; those details are in the attached Exhibit 99.1 press release.

Which exhibits are attached to the filing?

Exhibit 99.1 Exhibit 104 (Cover page Interactive Data File/Inline XBRL).

What exchange and ticker does the filing identify for Moleculin Biotech?

Common Stock, MBRX, listed on The NASDAQ Stock Market.

Who signed the Form 8-K on behalf of the company?

Jonathan P. Foster, Chief Financial Officer, signed the filing on behalf of the registrant.